1832 Asset Management L.P. Makes New Investment in Illumina, Inc. $ILMN

1832 Asset Management L.P. bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 16,544 shares of the life sciences company’s stock, valued at approximately $1,578,000.

Other large investors have also recently made changes to their positions in the company. Rise Advisors LLC lifted its holdings in Illumina by 173.6% during the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after buying an additional 224 shares in the last quarter. Parkside Financial Bank & Trust increased its position in shares of Illumina by 65.7% during the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 115 shares during the period. Cullen Frost Bankers Inc. bought a new stake in shares of Illumina during the second quarter valued at approximately $41,000. NewSquare Capital LLC boosted its holdings in shares of Illumina by 604.9% in the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock valued at $41,000 after purchasing an additional 369 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its stake in Illumina by 2,936.8% in the first quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock worth $46,000 after purchasing an additional 558 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Performance

ILMN stock opened at $128.96 on Friday. Illumina, Inc. has a one year low of $68.70 and a one year high of $153.06. The firm has a market cap of $19.71 billion, a price-to-earnings ratio of 28.91, a PEG ratio of 2.31 and a beta of 1.44. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43. The firm has a 50-day simple moving average of $111.21 and a two-hundred day simple moving average of $100.92.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.16 by $0.18. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the previous year, the business posted $1.14 EPS. Illumina’s revenue was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, equities analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Activity at Illumina

In other Illumina news, Director Scott Gottlieb acquired 500 shares of the stock in a transaction dated Monday, November 3rd. The stock was purchased at an average price of $122.13 per share, with a total value of $61,065.00. Following the transaction, the director directly owned 12,523 shares of the company’s stock, valued at $1,529,433.99. This trade represents a 4.16% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ILMN shares. Evercore ISI lifted their target price on Illumina from $132.00 to $142.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Daiwa America lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 12th. Cowen reiterated a “hold” rating on shares of Illumina in a report on Friday, October 31st. TD Cowen boosted their price target on shares of Illumina from $110.00 to $115.00 and gave the company a “hold” rating in a report on Friday, October 31st. Finally, Royal Bank Of Canada set a $124.00 price target on shares of Illumina in a research report on Tuesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $115.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.